Overall Diagnostic Performance of Multiple Versus Single Physical Examination Tests for the Prediction of Future Diabetic Neuropathy Risk
Journal of the Peripheral Nervous System · 2026-03 · 31 (1)
DOI: 10.1111/jns.70114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Peripheral Nervous System, online erschienen am 09.03.2026. Verfasst von Ethan Parikh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetic Neuropathies, Neurologic Examination, Physical Examination. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Diabetes Canada, Banting and Best Diabetes Centre, University of Toronto, The Menkes Fund.
Abstract (Originalsprache)
Background
The American Diabetes Association recommends three rather than one physical examination test for diabetic peripheral neuropathy (DPN) screening, although supporting evidence for the more complex screening strategy remains limited.
Aims
We aimed to determine if a three‐test strategy was superior to a single‐test in sensitively identifying early stages of neuropathy risk.
Methods
Using longitudinal data from 170 adults without DPN, we compared the overall accuracy, represented by the area under the receiver operating characteristic curve (AUC), for the three‐test versus one‐test strategies. These were conducted for monofilament, pinprick, and vibration sensation compared to the Sum of Abnormal Tests (primary analysis) or a model‐based probability from quantitative scores for each test in the prediction of nerve conduction study‐defined incident DPN.
Results
Incident DPN occurred in 53 (31%) participants over a mean 4‐year follow‐up. Predictive AUC for both the Sum of Abnormal Tests or the model‐based probability did not differ from the AUC for monofilament (0.66 vs. 0.71, p = 0.05 and 0.71 vs. 0.71, p = 0.79, respectively).
Interpretation
A complex three‐test strategy did not outperform the best‐performing single‐test strategy, implying that practice guidelines that recommend simplified approaches to neuropathy screening are valid.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
- Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Division of Endocrinology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
- Biostatistics Department, University Health Network, Toronto, Ontario, Canada.
- Weill Cornell Medicine-Qatar, Research Department, Doha, Qatar.
ORCID-Profile: Leif Erik Lovblom, Vera Bril, Bruce A Perkins
Förderung
- Diabetes Canada
- Banting and Best Diabetes Centre, University of Toronto
- The Menkes Fund
- BMO (Bank of Montreal)
- World Meteorological Organization
Zitieren
APA
Parikh, E., Al Mulla, A., Lovblom, L. E., Budhram, D. R., Orszag, A., Falappa, M., Gad, H., Bril, V., & Perkins, B. A. (2026). Overall Diagnostic Performance of Multiple Versus Single Physical Examination Tests for the Prediction of Future Diabetic Neuropathy Risk. Journal of the Peripheral Nervous System, 31(1). https://doi.org/10.1111/jns.70114
Vancouver
Parikh E, Al Mulla A, Lovblom LE, Budhram DR, Orszag A, Falappa M, et al. Overall Diagnostic Performance of Multiple Versus Single Physical Examination Tests for the Prediction of Future Diabetic Neuropathy Risk. Journal of the Peripheral Nervous System. 2026;31(1). doi:10.1111/jns.70114
BibTeX
@article{Parikh2026,
author = {Parikh, Ethan and Al Mulla, Abdulrhman and Lovblom, Leif Erik and Budhram, Dalton R and Orszag, Andrej and Falappa, Marcello and Gad, Hoda and Bril, Vera and Perkins, Bruce A},
title = {Overall Diagnostic Performance of Multiple Versus Single Physical Examination Tests for the Prediction of Future Diabetic Neuropathy Risk},
journal = {Journal of the Peripheral Nervous System},
year = {2026},
volume = {31},
number = {1},
doi = {10.1111/jns.70114}
}
EUVIMED